Diabetes Insights - Breakthroughs and Innovators

In this episode, Dr. Tamara Hannon (Indiana University Health) and Prof. Martin Wabitsch (Universtätsklinikum Ulm) unpack the findings of the SURPASS-PEDS trial - the first study to evaluate the dual GIP/GLP-1 receptor agonist tirzepatide in adolescents with type 2 diabetes. With youth-onset type 2 diabetes rising sharply across the US and Europe, and with young people experiencing faster beta-cel...

In this episode, EASD presents its inaugural clinical guideline on diabetes distress. Drawing on two years of multidisciplinary work, the guideline was developed by clinicians, methodologists, psychologists and people with lived experience. Prof. Jane Speight, Prof. Richard Holt and patient-advocate Michelle Law describe what diabetes distress is (the emotional burden tied to daily self-management...

In this episode, leading experts Anette Ziegler (Helmholtz Munich), Chantal Mathieu (KU Leuven & EASD President), and Anastasia Albanese-O’Neill (Breakthrough T1D) join EASD TV to discuss the emerging global consensus on screening for early-stage type 1 diabetes. They explore why population-wide screening is now considered both feasible and essential, how early detection can prevent DKA and enable...

Last week we heard the diabetologist's perspective on cardiovascular outcomes. In this weeks episode, EASD TV continues its deep dive into major clinical trials with the cardiologist’s perspective. Cardiologist Dr. Matthew Cavender (University of North Carolina) joins Vivienne Parry to unpack the SOUL trial, a major cardiovascular outcomes study evaluating oral semaglutide in people with type 2 di...

At the EASD 2024 Annual Meeting, the SOUL trial attracted significant attention as the first study to show cardiovascular risk reduction using an oral GLP-1 receptor agonist. In this episode, Dr Rodica Busui (Oregon Health & Science University-OHSU, Oregon, USA) explains the trial’s major outcomes, including a 14% reduction in major adverse cardiovascular events -matching results previously observ...

In this episode, Dr. Sean Wharton (University of Toronto and Wharton Medical Clinic, Canada) and Dr. Nasreen Alfaris (King Fahad Medical City, Riyadh, Saudi Arabia) join host Vivienne Parry to discuss the groundbreaking ATTAIN trial, presented at the EASD 2025 Annual Meeting in Vienna. The trial tested Orforglipron, the first oral small molecule GLP-1 receptor agonist, showing promising results in...

What does the future hold for beta cell biology and diabetes treatment? Join Prof. Raphaël Scharfmann (INSERM), recipient of the 2025 Albert Renold Prize, as he explores how developmental biology is unlocking new ways to generate functional beta cells - an important step toward curing diabetes. In this inspiring interview from the EASD 2025 Annual Meeting in Vienna, Prof. Scharfmann discusses the...

In this episode, Vivienne Parry introduces the EASD Rising Stars of 2025, four early-career researchers whose work spans exercise physiology, precision diabetes medicine, childhood obesity, and metabolic biology. Dr Sindre Lee-Ødegård (Norway) explores exercise as medicine for highrisk groups; Dr Martin Schön (Slovakia/Germany) works on precision diabetes diagnosis and lifestyle interventions; Dr...

In this episode, Dr. Viswanathan Mohan, recipient of the inaugural EASD Global Impact Prize, reflects on his remarkable 50-year career transforming diabetes care in India and worldwide. From pioneering diabetes as a medical speciality and training over 29,000 educators, to leading translational research and nationwide screening initiatives, Dr. Mohan’s work has set new benchmarks in global health...

In this episode, EASD TV host Vivienne Parry sits with Prof. Mikael Rydén (Karolinska Institute), recipient of the 40th Camillo Golgi Prize, about his groundbreaking research on adipose tissue. Prof. Rydén shares insights into how different fat cell subtypes influence disease progression, particularly in diabetes and obesity. His work highlights the potential of precision medicine in tailoring tre...

In this episode, Dr Teresa Mezza, recipient of the 2025 EASD Minkowski Prize, takes listeners inside her pioneering research on the early mechanisms of type 2 diabetes. As both a clinician and researcher at the Fondazione Policlinico Universitario A. Gemelli in Rome, Dr Mezza studies patients before and after partial pancreatectomy, offering a unique perspective on beta cell adaptation, function,...

In this episode, EASD host, Vivienne Parry sits down with 2025 EASD Claude Bernard Prize recipient, Prof. Andrew Hattersley, to reflect on his career which has transformed diabetes research and care worldwide. From the discovery of key genetic mutations in maturity onset diabetes of the young (MODY) and neonatal diabetes to establishing a global genetic testing programme that has helped patients i...

In this episode, we meet Prof Gerald Shulman, recipient of this year’s EASD-Novo Nordisk Foundation Diabetes Prize for Excellence, whose pioneering research has reshaped our understanding of insulin resistance and its role in type 2 diabetes and beyond. Prof. Shulman shares insights from over four decades of research into how ectopic lipid accumulation disrupts insulin signalling, leading to diabe...

In this special episode, host Vivienne Parry is joined by experts Anna Krook (Karolinska Institute), Klemen Dovč (Ljubljana University Medical Centre), Peter Gillard (University Hospital Leuven), and Julia Mader (University of Graz) to explore the rapid evolution of diabetes technology. From continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems to AI-powered apps and inte...

In this episode, Dr Andreas Birkenfeld (Germany) and Dr Viswanathan Mohan, 1st EASD Diabetes Global Impact Prize winner (India), join host Vivienne Parry to explore the growing importance of recognising, screening and managing pre-diabetes on a global scale. They discuss how moving beyond diabetes remission to pre-diabetes remission could prevent long-term complications, and why strategic, risk-ba...

What does the future hold for people living with diabetes? In this episode, our host Vivienne Parry together with diabetes advocates Bastian Hauck, Renza Scibilia and Christian Collin dives into recent advances in diabetes prevention, screening, and therapeutics - from GLP-1 drugs to innovative community-driven screening strategies. But as science accelerates, can our health systems and societies...

In this lively episode of Diabetes Insights, Prof. Francesco Rubino (King’s College London) and Dr. Louis Aronne (Weill Cornell Medicine) join Vivienne Parry to debate one of the biggest questions in obesity care: will next-generation medications make bariatric surgery obsolete? Drawing on decades of clinical experience and new trial evidence, they explore whether powerful GLP-1-based therapies an...

In this episode, Dr. Melissa Thomas (Eli, Lilly & Company), Dr. Elizabeth Niemoller (Sanofi) and Prof. Michele Solimena (Helmholtz Zentrum München & Technical University of Dresden) join host Vivienne Parry to examine how partnerships between academia and industry are transforming diabetes research and care. They discuss the culture shift from cautious collaboration to dynamic, mission-driven part...

Today on Diabetes Insights, Prof. Raphael Scharfmann (INSERM, France) and Dr. Valeria Sordi (San Raffaele Diabetes Research Institute, Italy) join our host, Vivienne Parry to discuss the progress and remaining challenges in creating functional, insulin-producing beta cells from stem cells. From the fundamental biology of pancreatic development to translational protocols for generating clinical-gra...

In this episode, Professors Hood Thabit (University of Manchester, UK) and Helen Murphy (University of East Anglia, Norwich, UK) join Vivienne Parry and EASD to discuss the opportunities and persistent challenges in diabetes care in hospitals and pregnancy. The conversation examines how diabetes technology - from continuous glucose monitoring (CGM) to hybrid closed-loop systems - is improving outc...

In this episode, we explore the fascinating history, fall, and resurgence of GIP (glucose-dependent insulinotropic polypeptide) in diabetes therapy. Once overshadowed by GLP-1, GIP is now back in the spotlight, thanks to dual and triple agonist therapies like tirzepatide. Experts discuss how GIP signaling in the brain may influence appetite and weight regulation, why early studies underestimated i...

In this episode, we explore the evolving world of cell therapy in type 1 diabetes. Professor James Shaw (Newcastle University), Dr Timothy Kieffer (University of British Columbia & Fractal Health), and Dr Trevor Reichman (University of Toronto) join EASD to discuss the established role of islet transplants and the exciting promise of stem cell–derived islets. The conversation covers the clinical r...

Today’s episode is special, as the topic was requested by members of the Early Career Academy. The spotlight is on work-life balance in academic medicine and research. Dr Anna Krook from the Karolinska Institute in Sweden and Dr Benoit Gauthier from the Andalusian Molecular Biology and Regenerative Medicine Centre – CABIMER with the Ministry of Health of Andalusia in Spain, delve into the critical...

In this episode Diabetes Perspectives, Prof. Partha Kar, National Specialty Advisor for Diabetes with NHS England, shares how the UK became the first country in the world to offer universal access to continuous glucose monitors and hybrid closed-loop systems for people with type 1 diabetes. Prof. Kar discusses the challenges of clinical inertia, the crucial role of patient advocacy, and how data-d...

In this episode, Prof. Emma Ahlqvist (Lund University) and Prof. Matthias Blüher (University of Leipzig) join host Vivienne Parry to explore the future of type 2 diabetes. They unpack the shift from a one-size-fits-all approach to one that embraces stratified and personalised care. From using machine learning to define diabetes subtypes to applying AI tools for screening, they share how new approa...